AlzeCure Pharma (ALZCUR) Q2 2026 earnings summary

Executive summary

• Achieved two major out-licensing and collaboration agreements for Alzheimer's projects with Eli Lilly and QuantumCell ApS, with combined potential deal value exceeding USD 3.2 billion, excluding royalties.

• Strengthened cash position through a heavily oversubscribed rights issue, raising over SEK 30 million.

• Positive clinical and preclinical results across Alzheimer's and pain portfolios, with significant progress in both NeuroRestore and Painless platforms.

Financial highlights

• Q2 2026 net sales reached SEK 97,326 thousand, compared to SEK 0 in Q2 2025, driven by the Eli Lilly upfront payment.

• Earnings for Q2 2026 totaled SEK 80,181 thousand, up from a loss of SEK -9,758 thousand in Q2 2025.

• Basic earnings per share for Q2 2026 were SEK 0.70, compared to SEK -0.11 in Q2 2025.

• Cash and cash equivalents at period end were SEK 13,491 thousand, up from SEK 12,576 thousand a year earlier.

• Total assets increased to SEK 122,368 thousand from SEK 20,642 thousand year-over-year.

Outlook and guidance

• Focus on successful execution of new collaboration agreements and acceleration of pain project development.

• Continued business development efforts for out-licensing of pain projects, with ongoing discussions with potential partners.

• Preparations underway for Phase IIa clinical trial of NeuroRestore ACD856 in Alzheimer's patients, planned to start in 2026.